PepGen Inc. (PEPG) - Q3 2024 10-Q Summary
Business Context and Reporting Period
PepGen Inc. is a clinical-stage biotechnology company developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases, specifically Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The company utilizes its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. This report covers the quarterly period ended September 30, 2024. As of November 1, 2024, the company had 32,595,737 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(21.4) million | $(23.3) million | $(67.7) million | $(59.1) million |
| Operating Expenses | $23.2 million | $24.8 million | $73.4 million | $64.0 million |
| Research & Development | $17.7 million | $20.5 million | $57.5 million | $51.8 million |
| General & Administrative | $5.4 million | $4.2 million | $15.9 million | $12.1 million |
| Cash & Cash Equivalents | $42.3 million | $80.8 million (Dec 31, 2023) | Total Liquidity (Cash + Marketable Securities): $138.9 million as of Sept 30, 2024 | |
| Marketable Securities | $96.6 million | $29.6 million (Dec 31, 2023) | ||
| Accumulated Deficit | $(249.2) million | $(181.5) million (Dec 31, 2023) | N/A | |
| Net Cash Used in Operating Activities | N/A | N/A | $(62.9) million | $(49.6) million |
Material Changes vs. Prior Period
- Net Loss: The net loss for the three months ended September 30, 2024, decreased by $1.9 million compared to the same period in 2023, primarily due to a reduction in research and development expenses.
- R&D Expenses: Q3 2024 R&D expenses decreased by $2.8 million year-over-year. This was driven by a $3.8 million decrease in manufacturing costs and a $2.7 million decrease in preclinical costs as lead programs advanced to clinical trials. These savings were partially offset by increased clinical trial costs ($1.0 million) and personnel-related costs ($1.7 million).
- G&A Expenses: Increased by $1.2 million in Q3 2024 compared to Q3 2023, primarily due to increased headcount and stock-based compensation.
- Liquidity Position: Cash and cash equivalents decreased from $80.8 million at year-end 2023 to $42.3 million at Q3 2024, while marketable securities increased significantly from $29.6 million to $96.6 million. Total liquidity remains robust at $138.9 million.
- Financing Activity: In February 2024, the company raised $86.3 million in net proceeds through a Follow-on Offering ($76.4 million) and an At-the-Market (ATM) sale ($9.9 million).
Guidance, Outlook, and Risks
- Clinical Progress:
- PGN-EDO51 (DMD): The CONNECT1 Phase 2 study reported initial data showing mean exon skipping of 2.15% and dystrophin levels of 1.49% of normal in the 5 mg/kg cohort. The study protocol was amended to adjust biopsy timing and age eligibility. The CONNECT2 Phase 2 study received clearance in the UK and is expected to file an IND in the U.S. by year-end 2024.
- PGN-EDODM1 (DM1): The FREEDOM Phase 1 study is ongoing. The FREEDOM2 Phase 2 study received clearance in Canada and the UK, with patient dosing expected to initiate in Q4 2024.
- Liquidity Outlook: Management believes current cash, cash equivalents, and marketable securities ($138.9 million) are sufficient to fund operations into 2026.
- Key Risks:
- Capital Needs: The company has no approved products and expects to incur losses for the foreseeable future. Additional funding will be required to advance clinical trials and commercialize products.
- Development Uncertainty: Clinical trials are expensive and uncertain; early data may not predict later results. The company faces risks related to patient enrollment, regulatory approvals, and manufacturing.
- Competition: Significant competition exists in DMD and DM1 treatment spaces from large pharmaceutical companies and other biotechs.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $138.9 million liquidity position against the projected burn rate to confirm the "into 2026" funding estimate.
- Clinical Data Validation: Review the full data release from the CONNECT1 Phase 2 study (5 mg/kg cohort) to assess the clinical significance of the reported exon skipping and dystrophin levels.
- Regulatory Milestones: Monitor the status of the IND filing for the CONNECT2 study in the U.S. and the initiation of dosing for the FREEDOM2 study in Q4 2024.
- Expense Trends: Track the trajectory of R&D expenses as the company scales up clinical operations for two parallel Phase 2 programs.
- Capital Markets: Assess the company's ability to raise additional capital if needed, given the volatility in the biotech sector and the dilution impact of future equity offerings.